Publications: Prof James Lindsay
Peyrin-Biroulet L, Chapman JC, Colombel J-F, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R et al.
(
2024
)
.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
.
New England Journal of Medicine
vol.
391
,
(
3
)
213
-
223
.
Rodger B, Stagg AJ, Lindsay JO
(
2024
)
.
The role of circulating T cells with a tissue resident phenotype (ex-TRM) in health and disease
.
Frontiers in Immunology
vol.
15
,
Tyler CJ, Hoti I, Griffiths DD, Cuff SM, Andrews R, Keisker M, Ahmed R, Hansen HP et al.
(
2024
)
.
IL-21 conditions antigen-presenting human γδ T-cells to promote IL-10 expression in naïve and memory CD4+ T-cells
.
Discovery Immunology
vol.
3
,
(
1
)
Humphreys DT, Lewis A, Pan‐Castillo B, Berti G, Mein C, Wozniak E, Gordon H, Gadhok R et al.
(
2024
)
.
Single cell sequencing data identify distinct B cell and fibroblast populations in stricturing Crohn's disease
.
Journal of Cellular and Molecular Medicine
vol.
28
,
(
9
)
Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, Allerton D, Bardgett M et al.
(
2024
)
.
Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine
.
BMJ Open
vol.
14
,
(
4
)
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ et al.
(
2024
)
.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
.
Clinical Gastroenterology and Hepatology
vol.
22
,
(
10
)
2096
-
2106
.
Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ et al.
(
2024
)
.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
.
The Lancet Gastroenterology & Hepatology
vol.
9
,
(
5
)
415
-
427
.
Whelan K, Bancil AS, Lindsay JO, Chassaing B
(
2024
)
.
Ultra-processed foods and food additives in gut health and disease
.
Nature Reviews Gastroenterology & Hepatology
vol.
21
,
(
6
)
406
-
427
.
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B et al.
(
2024
)
.
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
.
EClinicalMedicine
vol.
69
,
Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C et al.
(
2024
)
.
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial
.
The Lancet Gastroenterology & Hepatology
vol.
9
,
(
4
)
333
-
345
.
D'Haens G, Sands BE, Ferrante M, Matsuoka K, Lindsay JO, Blumenstein I, Mehra D, Charles L et al.
(
2024
)
.
P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
.
Journal of Crohn's and Colitis
vol.
18
,
(
Supplement_1
)
i1823
-
i1824
.
Blumenstein I, Torres J, Ma C, Lindsay JO, Ungaro R, Thin L, Lacerda AP, Anyanwu SI et al.
(
2024
)
.
P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease
.
Journal of Crohn's and Colitis
vol.
18
,
(
Supplement_1
)
i1007
-
i1008
.
Long MD, Schreiber S, Hibi T, Gibble TH, Fisher DA, Park G, Moses RE, Higgins PDR et al.
(
2024
)
.
Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies
.
Crohn's & Colitis 360
vol.
6
,
(
1
)
Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C et al.
(
2024
)
.
Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn's disease: the ASTIClite RCT
.
Efficacy and Mechanism Evaluation
vol.
11
,
(
3
)
1
-
106
.
Lewis A, Humphreys DT, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Nijhuis A et al.
(
2023
)
.
Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn’s Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets
.
Journal of Crohn's and Colitis
vol.
18
,
(
6
)
895
-
907
.
Peyrin-Biroulet L, Chapman C, Colombel J-F, Caprioli F, D’Haens G, Ferrante M, Schreiber S, Atreya R et al.
(
2023
)
.
S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial
.
The American Journal of Gastroenterology
vol.
118
,
(
12S
)
s1
-
s1
.
Watanabe K, Peyrin-Biroulet L, Danese S, Fujitani Y, Faes M, Oortwijn A, Lindsay JO, Rogler G et al.
(
2023
)
.
Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study
.
Journal of Crohn's and Colitis
vol.
18
,
(
6
)
801
-
811
.
Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR et al.
(
2023
)
.
Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis
.
Alimentary Pharmacology & Therapeutics
vol.
59
,
(
3
)
393
-
408
.
Carlson SL, Mathew L, Savage M, Kok K, Lindsay JO, Munro CA, McCarthy NE
(
2023
)
.
Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease
.
Journal of Fungi
vol.
9
,
(
11
)
Gordon H, Wichmann K, Lewis A, Sanders T, Wildemann M, Hoti I, Hornsby E, Kok KB et al.
(
2023
)
.
Human Intestinal Dendritic Cells Can Overcome Retinoic Acid Signaling to Generate Proinflammatory CD4 T Cells with Both Gut and Skin Homing Properties
.
The Journal of Immunology
vol.
212
,
(
1
)
96
-
106
.
Vieujean S, Lindsay JO, D'Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK, Nagahori M et al.
(
2023
)
.
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD
.
Journal of Crohn's and Colitis
vol.
18
,
(
4
)
548
-
559
.
Panaccione R, Panés J, Peyrin-Biroulet L, Colombel J-F, Lindsay J, Baert F, Atreya R, Lacerda AP et al.
(
2023
)
.
S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
.
The American Journal of Gastroenterology
vol.
118
,
(
10S
)
s909
-
s910
.
Bai BYH, Reppell M, Smaoui N, Waring JF, Pivorunas V, Guay H, Lin S, Chanchlani N et al.
(
2023
)
.
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
.
Journal of Crohn's and Colitis
vol.
18
,
(
3
)
431
-
445
.
Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S et al.
(
2023
)
.
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
.
The Lancet Gastroenterology & Hepatology
vol.
8
,
(
11
)
976
-
989
.
Mehandru S, Colombel J-F, Juarez J, Bugni J, Lindsay JO
(
2023
)
.
Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease
.
Mucosal Immunology
vol.
16
,
(
6
)
859
-
870
.
Lim SH, Gros B, Sharma E, Lehmann A, Lindsay JO, Caulfield L, Gaya DR, Taylor J et al.
(
2023
)
.
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
.
Inflammatory Bowel Diseases
vol.
30
,
(
8
)
1284
-
1294
.
Wong S-Y, Wellens J, Helmus D, Marlow L, Brann S, Pazos VM, Weinberg A, Moran HR et al.
(
2023
)
.
Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium
.
Inflammatory Bowel Diseases
vol.
29
,
(
11
)
1693
-
1705
.
Ventham NT, Kennedy NA, Kalla R, Adams AT, Noble A, Ennis H, Group TS, Arnott I et al.
(
2023
)
.
Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
.
Cellular and Molecular Gastroenterology and Hepatology
vol.
16
,
(
3
)
431
-
450
.
Lindsay JO, Picker N, Kromer D, Smyth M, Patel H
(
2023
)
.
The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom
.
Current Medical Research and Opinion
vol.
39
,
(
5
)
681
-
689
.
Lu X, Zhou Z-Y, Xin Y, Wang M-J, Gray E, Jairath V, Lindsay JO
(
2024
)
.
Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis
.
Inflammatory Bowel Diseases
.
vol.
30
,
64
-
77
.
Gordon H, Rodger B, Lindsay JO, Stagg AJ
(
2023
)
.
Recruitment and Residence of Intestinal T Cells – Lessons for Therapy in Inflammatory Bowel Disease
.
Journal of Crohn's and Colitis
vol.
17
,
(
8
)
1326
-
1341
.
Alexander JL, Wyatt NJ, Camuzeaux S, Chekmeneva E, Jimenez B, Sands CJ, Fuller H, Takis P et al.
(
2023
)
.
Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research
.
Gut
vol.
73
,
(
2
)
379
-
383
.
Hornsby E, Gadhok R, Yadon AN, Lindsay JO, Stagg AJ
(
2023
)
.
DOP04 Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn’s Disease
.
Journal of Crohn's and Colitis
vol.
17
,
(
Supplement_1
)
i61
-
i62
.
Roukas C, Miller L, Hamborg T, Gordeev V, Lindsay J, Norton C, Mihaylova B
(
2023
)
.
DOP23 Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey
.
Journal of Crohn's and Colitis
vol.
17
,
(
Supplement_1
)
i87
-
i88
.
Feagan BG, Horst S, Dryden G, Lindsay JO, Ferrante M, Dubenco E, Lacerda AP, Ford S et al.
(
2023
)
.
OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
.
Journal of Crohn's and Colitis
vol.
17
,
(
Supplement_1
)
i22
-
i25
.
Vieujean S, Lindsay JO, Rubin D, D’Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK et al.
(
2023
)
.
P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
.
Journal of Crohn's and Colitis
vol.
17
,
(
Supplement_1
)
i794
-
i797
.
Panés J, Loftus EV, Higgins PDR, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C et al.
(
2023
)
.
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
.
Inflammatory Bowel Diseases
vol.
29
,
(
9
)
1421
-
1430
.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L et al.
(
2023
)
.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
.
The Lancet Gastroenterology & Hepatology
vol.
8
,
(
3
)
215
-
227
.
collaborators TEC
(
2022
)
.
Development of a core descriptor set for Crohn's anal fistula
.
Colorectal Disease
vol.
25
,
(
4
)
695
-
706
.
Cox SR, Czuber-Dochan W, Wall CL, Clarke H, Drysdale C, Lomer MC, Lindsay JO, Whelan K
(
2022
)
.
Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial
.
Nutrients
vol.
14
,
(
20
)
Lewis A, Sánchez S, Berti G, Pan-Castillo B, Nijhuis A, Mehta S, Eleid L, Gordon H et al.
(
2022
)
.
Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease
.
Clinical Science
vol.
136
,
(
19
)
1405
-
1423
.
Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S et al.
(
2022
)
.
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study
.
Alimentary Pharmacology & Therapeutics
vol.
56
,
(
10
)
1460
-
1474
.
Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G et al.
(
2022
)
.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
.
The Lancet
vol.
399
,
(
10341
)
2113
-
2128
.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG et al.
(
2022
)
.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
.
The Lancet
vol.
399
,
(
10340
)
2015
-
2030
.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG et al.
(
2022
)
.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
.
The Lancet
vol.
399
,
(
10340
)
2031
-
2046
.
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT et al.
(
2022
)
.
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
.
The Lancet Gastroenterology & Hepatology
vol.
7
,
(
7
)
666
-
678
.
Wellens J, Brann S, Adams A, Marlow L, Lindsay JO, Satsangi JJ
(
2022
)
.
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease
.
The Lancet Gastroenterology & Hepatology
vol.
7
,
(
6
)
Hornsby E, King HW, Peiris M, Buccafusca R, Lee W-YJ, Wing ES, Blackshaw LA, Lindsay JO et al.
(
2022
)
.
The cation channel TRPM8 influences the differentiation and function of human monocytes
.
Journal of Leukocyte Biology
vol.
112
,
(
3
)
365
-
381
.
Wellens J, Edmans M, Obolski U, Marlow L, Brann S, Dunachie S, Eyre D, Helmus D et al.
(
2022
)
.
DOP20 Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i069
-
i070
.
Mathew L, Savage M, Pardieu C, O’Brien M, Sze SK, Eberl M, Stagg A, Gasparetto M et al.
(
2022
)
.
OP37 Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i043
-
i044
.
Rodger B, Gordon H, Hoti I, Stagg A, Lindsay J
(
2022
)
.
P003 Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i136
-
i136
.
Gordon H, Rodger B, Hornsby E, McGuire J, Kok KB, Lindsay JO, Stagg AJ
(
2022
)
.
P039 The role of α4β7+CLA+ ‘dual tropic’ T cells in inflammatory bowel disease
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i156
-
i156
.
Lindsay J, Picker N, Kromer D, Smyth M, Patel H
(
2022
)
.
P389 Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i387
-
i388
.
Hosack T, Gadhok R, Lindsay JO
(
2022
)
.
P584 Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease
.
Journal of Crohn's and Colitis
vol.
16
,
(
Supplement_1
)
i523
-
i523
.
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V et al.
(
2022
)
.
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
.
The Lancet Gastroenterology & Hepatology
vol.
7
,
(
3
)
254
-
261
.
Raine T, Pavey H, Qian W, Moran GW, Subramanian S, Swaby L, Travis SP, Din S et al.
(
2022
)
.
Establishment of a validated central reading system for ileocolonoscopy in an academic setting
.
Gut
vol.
71
,
(
4
)
661
-
664
.
Mathew L, Savage M, Pardieu C, O'Brien M, Sze SK, Eberl M, Stagg A, Gasparetto M et al.
(
2022
)
.
Bacterial suppression of intestinal fungi via activation of human gut Vδ2+T-cells
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I043
-
I044
.
Vermeire S, Danese S, Zhou W, Yao X, Ilo D, Liu J, Hebuterne X, Lindsay J et al.
(
2022
)
.
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study
.
AMERICAN JOURNAL OF GASTROENTEROLOGY
.
vol.
117
,
S521
-
S522
.
Wellens J, Edmans M, Obolski U, Marlow L, Brann S, Dunachie S, Eyre D, Helmus D et al.
(
2022
)
.
Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I069
-
I070
.
Rodger B, Gordon H, Hoti I, Stagg A, Lindsay J
(
2022
)
.
Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I136
-
I136
.
Lindsay J, Picker N, Kromer D, Smyth M, Patel H
(
2022
)
.
Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I387
-
I388
.
Panes J, Loftus EVJ, Higgins P, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C et al.
(
2022
)
.
Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I373
-
I374
.
Hosack T, Gadhok R, Lindsay JO
(
2022
)
.
Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I523
-
I523
.
Gordon H, Rodger B, Hornsby E, McGuire J, Kok KB, Lindsay JO, Stagg AJ
(
2022
)
.
The role of α4β7+CLA+ 'dual tropic' T cells in inflammatory bowel disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I156
-
I156
.
Wong SY, Helmus D, Marlow L, Pazos VM, Brann S, Wellens J, Kedia S, Mak JWY et al.
(
2022
)
.
Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
.
JOURNAL OF CROHNS & COLITIS
.
vol.
16
,
I357
-
I358
.
Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D et al.
(
2021
)
.
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
.
Gut
vol.
71
,
(
9
)
1919
-
1922
.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV et al.
(
2021
)
.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
.
The Lancet Gastroenterology & Hepatology
vol.
7
,
(
2
)
128
-
140
.
Danese S, Colombel J-F, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim H-S et al.
(
2021
)
.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
.
The Lancet Gastroenterology & Hepatology
vol.
7
,
(
2
)
118
-
127
.
Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, Mahida Y, Moran G et al.
(
2021
)
.
OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite
.
Gut
.
Conference:
Oral
vol.
70
,
a4
-
a4
.
McCartney S, Lindsay JO, Russell RK, Gaya DR, Shaw I, Murray CD, Finney‐Hayward T, Sebastian S
(
2021
)
.
Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
.
Journal of Pediatric Gastroenterology and Nutrition
vol.
74
,
(
2
)
208
-
214
.
Alexander T, Snowden JA, Burman J, Chang H-D, Del Papa N, Farge D, Lindsay JO, Malard F et al.
(
2021
)
.
Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT
.
Frontiers in Oncology
vol.
11
,
Wilson B, Eyice Ö, Koumoutsos I, Lomer MC, Irving PM, Lindsay JO, Whelan K
(
2021
)
.
Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms
.
Nutrients
vol.
13
,
(
10
)
Schreiber S, Ferrante M, Panaccione R, Colombel J-F, Hisamatsu T, Lim A, Lindsay J, Rubin DT et al.
(
2021
)
.
S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
.
The American Journal of Gastroenterology
vol.
116
,
(
1
)
s314
-
s315
.
Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D’Haens G, Panés J, Juillerat P et al.
(
2021
)
.
S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
.
The American Journal of Gastroenterology
vol.
116
,
(
1
)
s357
-
s357
.
Feagan B, Lindsay J, Rogler G, Moran G, Varawalla N
(
2021
)
.
S785 Alicaforsen Enema in Chronic Pouchitis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Trial
.
The American Journal of Gastroenterology
vol.
116
,
(
1
)
s365
-
s365
.
Cox SR, Clarke H, O’Keeffe M, Dubois P, Irving PM, Lindsay JO, Whelan K
(
2021
)
.
Nutrient, Fibre, and FODMAP Intakes and Food-related Quality of Life in Patients with Inflammatory Bowel Disease, and Their Relationship with Gastrointestinal Symptoms of Differing Aetiologies
.
Journal of Crohn's and Colitis
vol.
15
,
(
12
)
2041
-
2053
.
Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Stagg AJ, Lindsay JO, Whelan K
(
2021
)
.
Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease
.
Clinical Nutrition
vol.
40
,
(
8
)
5009
-
5019
.
Lewis A, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Minicozzi A, Chinaleong J et al.
(
2021
)
.
DOP23 Single-cell RNA sequencing identifies an important role for class I histone-deacetylase enzymes in intestinal myofibroblasts from patients with Crohn’s Disease strictures
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s062
-
s062
.
Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D’Haens G, Panes J, Juillerat P et al.
(
2021
)
.
OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s021
-
s022
.
Schreiber SW, Ferrante M, Panaccione R, Colombel JF, Hisamatsu T, Lim A, Lindsay JO, Rubin DT et al.
(
2021
)
.
OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s026
-
s027
.
Rodger B, Hoti I, Gordon H, Lindsay J, Stagg A
(
2021
)
.
P007 Identification and characterisation of intestine-derived circulating resident memory T cells (ex-Trm) in health and Inflammatory Bowel Disease
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s128
-
s128
.
Gordon H, Rodger B, Hoti I, Lindsay JO, Stagg A
(
2021
)
.
P033 Dendritic cells from patients with active IBD imprint pro-inflammatory α4β7+CLA+ T cells with potential for gut and skin homing
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s147
-
s147
.
Hornsby E, Yadon AN, Clarke A, Grant E, Lindsay JO, Stagg AJ
(
2021
)
.
P068 The combination of JAK1 and TPL2 or IRAK4 inhibitors is more effective than single agents in reducing TLR-mediated cytokine responses in human monocyte populations
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s173
-
s173
.
Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A
(
2021
)
.
P079 Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s181
-
s181
.
Kabir M, Curtius K, Kalia P, Al Bakir I, Choi CHR, Hartono JL, East JE, Lindsay JO et al.
(
2021
)
.
P109 Impact of ethnicity on colorectal cancer incidence in a cohort of colitis-associated dysplasia patients
.
Journal of Crohn's and Colitis
vol.
15
,
(
Supplement_1
)
s201
-
s202
.
Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE, Lindsay JO et al.
(
2021
)
.
Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool
.
Gut
Dubinsky MC, Collins R, Abreu MT, Diseases IOFTSOIB, Abreu MT, Collins R, Dubinsky MC, Jairath V et al.
(
2021
)
.
Challenges and Opportunities in IBD Clinical Trial Design
.
Gastroenterology
vol.
161
,
(
2
)
400
-
404
.
Wong S-Y, Dixon R, Pazos VM, Gnjatic S, Colombel J-F, Cadwell K, Group I-IW, Gold S et al.
(
2021
)
.
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
.
Gastroenterology
vol.
161
,
(
2
)
715
-
718.e4
.
Whelan K, Murrells T, Morgan M, Cummings F, Stansfield C, Todd A, Sebastian S, Lobo A et al.
(
2021
)
.
Food-related quality of life is impaired in inflammatory bowel disease and associated with reduced intake of key nutrients
.
American Journal of Clinical Nutrition
vol.
113
,
(
4
)
832
-
844
.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel J-F, Flynn HA, Huyck S, Yao R et al.
(
2021
)
.
Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab
.
Inflammatory Bowel Diseases
vol.
27
,
(
12
)
1963
-
1967
.
McGregor CG, Adams A, Sadler R, Arancibia-Cárcamo CV, Palmer R, Ambrose T, Brain O, Walsh A et al.
(
2021
)
.
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
.
Gut
vol.
70
,
(
12
)
2398
-
2400
.
Kim H, Alten R, Cummings F, Danese S, D’Haens G, Emery P, Ghosh S, de Saint Joseph CG et al.
(
2021
)
.
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
.
mAbs
vol.
13
,
(
1
)
Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP et al.
(
2021
)
.
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
.
The Lancet Gastroenterology & Hepatology
vol.
6
,
(
4
)
271
-
281
.
Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J et al.
(
2021
)
.
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
.
The Lancet Gastroenterology & Hepatology
vol.
6
,
(
3
)
218
-
224
.
Curtius K, Kabir M, Bakir IA, Choi C-HR, Hartono J, Johnson M, East JE, Lindsay JO et al.
(
2021
)
.
O17 Multi-centre validation of UC-CaRE: a cancer risk prediction tool for colitis-associated low grade dysplasia
.
Gut
.
Conference:
Oral
vol.
70
,
a9
-
a10
.
Gadhok R, Honap S, Ibarra A, Burgess N, Parkes G, Samaan M, Ray S, Mawdsley J et al.
(
2021
)
.
P103 Ustekinumab: medium-term outcomes from a uk multi-centre real-world cohort
.
Gut
.
Conference:
Posters
vol.
70
,
a94
-
a95
.
Gordon H, Hoti I, Wichmann K, Saunders T, Wildemann M, Hornsby E, McCarthy NE, Lindsay JO et al.
(
2021
)
.
P105 Dendritic cells imprint pro-inflammatory α4β7+CLA+ T cells with potential for gut and skin homing
.
Gut
.
Conference:
Posters
vol.
70
,
a95
-
a96
.
Kabir M, Curtius K, Al-Bakir I, Choi C-HR, Hartono J, Johnson M, East JE, Lindsay JO et al.
(
2021
)
.
P115 Low grade dysplasia prognosis in the 21st century – a large multi-centre retrospective cohort study
.
Gut
.
Conference:
Posters
vol.
70
,
a101
-
a102
.
Feagan B, Lindsay J, Rogler G, Moran G, Varawalla N
(
2021
)
.
Alicaforsen Enema in Chronic Pouchitis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Trial
.
AMERICAN JOURNAL OF GASTROENTEROLOGY
.
vol.
116
,
S364
-
S364
.
Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D'Haens G, Panes J, Juillerat P et al.
(
2021
)
.
Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
.
AMERICAN JOURNAL OF GASTROENTEROLOGY
.
vol.
116
,
S357
-
S357
.
Schreiber S, Ferrante M, Panaccione R, Colombel J-F, Hisamatsu T, Lim A, Lindsay J, Rubin DT et al.
(
2021
)
.
Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
.
AMERICAN JOURNAL OF GASTROENTEROLOGY
.
vol.
116
,
S314
-
S315
.
Lewis A, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Minicozzi A, Chinaleong J et al.
(
2021
)
.
Single-cell RNA sequencing identifies an important role for class I histone-deacetylase enzymes in intestinal myofibroblasts from patients with Crohn's Disease strictures
.
JOURNAL OF CROHNS & COLITIS
.
vol.
15
,
S062
-
S062
.
Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A
(
2021
)
.
Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
15
,
S181
-
S181
.
Bancil AS, Sandall AM, Rossi M, Chassaing B, Lindsay JO, Whelan K
(
2020
)
.
Food Additive Emulsifiers and Their Impact on Gut Microbiome, Permeability, and Inflammation: Mechanistic Insights in Inflammatory Bowel Disease
.
Journal of Crohn's and Colitis
vol.
15
,
(
6
)
1068
-
1079
.
Felice C, Lewis A, Iqbal S, Gordon H, Rigoni A, Colombo MP, Armuzzi A, Feakins R et al.
(
2020
)
.
Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients
.
Cellular and Molecular Gastroenterology and Hepatology
vol.
11
,
(
3
)
Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K et al.
(
2020
)
.
Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics
.
Clinical Nutrition
vol.
40
,
(
4
)
1861
-
1870
.
Dotan I, Panaccione R, Kaplan GG, O’Morain C, Lindsay JO, Abreu MT
(
2020
)
.
Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force
.
Journal of Crohn's and Colitis
vol.
14
,
(
Supplement_3
)
s785
-
s790
.
Sandall AM, Cox SR, Lindsay JO, Gewirtz AT, Chassaing B, Rossi M, Whelan K
(
2020
)
.
Emulsifiers Impact Colonic Length in Mice and Emulsifier Restriction is Feasible in People with Crohn’s Disease
.
Nutrients
vol.
12
,
(
9
)
Ball J, Clear A, Aries J, Charrot S, Besley C, Mee M, Stagg A, Lindsay J et al.
(
2020
)
.
Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD
.
Blood
Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA et al.
(
2020
)
.
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
.
The Lancet Gastroenterology & Hepatology
vol.
5
,
(
7
)
679
-
697
.
Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie M, Din S, Lamb CA, Smith PJ et al.
(
2020
)
.
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
.
Frontline Gastroenterology
vol.
11
,
(
5
)
Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F et al.
(
2020
)
.
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
.
Gut
vol.
69
,
(
10
)
1769
-
1777
.
Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ et al.
(
2020
)
.
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
.
Gut
Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al.
(
2020
)
.
Tu1814 MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL
.
Gastroenterology
vol.
158
,
(
6
)
Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al.
(
2020
)
.
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply
.
Alimentary Pharmacology & Therapeutics
vol.
51
,
(
10
)
997
-
998
.
Curtius K, Kabir M, Al Bakir I, Choi C-HR, Hartono J, Johnson M, East JE, Investigators OICS et al.
(
2020
)
.
Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool
.
Rubin DT, Abreu MT, Rai V, Siegel CA, Disease IOFTSOIB, Ahuja V, Allez M, Ananthakrishnan AN et al.
(
2020
)
.
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
.
Gastroenterology
vol.
159
,
(
1
)
6
-
13.e6
.
Levine A, Rhodes JM, Lindsay JO, Abreu MT, Kamm MA, Gibson PR, Gasche C, Silverberg MS et al.
(
2020
)
.
Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases
.
Clinical Gastroenterology and Hepatology
vol.
18
,
(
6
)
1381
-
1392
.
Sandall A, Cox S, Lindsay JO, Rossi M, Whelan K
(
2020
)
.
Food additive emulsifier restriction is feasible in people with Crohn's disease
.
Proceedings of The Nutrition Society
vol.
79
,
(
OCE1
)
Kabir M, Curtius K, Al-Bakir I, Hartono J, Johnson M, East JE, Lindsay JO, Vega R et al.
(
2020
)
.
DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
.
Journal of Crohn's and Colitis
vol.
14
,
(
Supplement_1
)
s078
-
s079
.
Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Zeroncio M et al.
(
2020
)
.
DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
.
Journal of Crohn's and Colitis
vol.
14
,
(
Supplement_1
)
s110
-
s111
.
Gadhok R, Fragkos K, Honap S, Hassan J, Whiteley L, Ibarra A, Burgess N, Vega R et al.
(
2020
)
.
P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort
.
Journal of Crohn's and Colitis
vol.
14
,
(
Supplement_1
)
s439
-
s440
.
Staudacher H, Scholz M, Lomer M, Ralph F, Irving P, Lindsay J, Fava F, Tuohy K et al.
(
2020
)
.
Diet and the microbiota in irritable bowel syndrome: Baseline associations and the impact of dietary intervention
.
NEUROGASTROENTEROLOGY AND MOTILITY
.
vol.
32
,
Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Zeroncio M et al.
(
2020
)
.
Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study
.
JOURNAL OF CROHNS & COLITIS
.
vol.
14
,
S110
-
S111
.
Gordon H, Murray J, Tailor F, Goh SA, Lindsay JO
(
2020
)
.
Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission
.
JOURNAL OF CROHNS & COLITIS
.
vol.
14
,
S471
-
S471
.
Kabir M, Curtius K, Al-Bakir I, Hartono J, Johnson M, East JE, Lindsay JO, Vega R et al.
(
2020
)
.
Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
.
JOURNAL OF CROHNS & COLITIS
.
vol.
14
,
S078
-
S079
.
Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al.
(
2020
)
.
MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL
.
GASTROENTEROLOGY
.
vol.
158
,
S1172
-
S1173
.
Wilson B, Rossi M, Eyice O, Lomer MC, Irving PM, Lindsay JO, Whelan K
(
2020
)
.
Prebiotic β-galacto-oligosaccharide impact on clinical, inflammatory and microbiota outcomes in active ulcerative colitis: An open-label study
.
Proceedings of the Nutrition Society
.
Conference:
Nutrition Society
Gadhok R, Fragkos K, Honap S, Hassan J, Whiteley L, Ibarra A, Burgess N, Vega R et al.
(
2020
)
.
Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort
.
JOURNAL OF CROHNS & COLITIS
.
vol.
14
,
S439
-
S440
.
Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al.
(
2019
)
.
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
.
Alimentary Pharmacology & Therapeutics
vol.
51
,
(
2
)
271
-
280
.
Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Abbott JE, Michael E, Ahmad OF et al.
(
2019
)
.
UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients
.
Digestive Diseases and Sciences
vol.
65
,
(
6
)
1790
-
1799
.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N et al.
(
2019
)
.
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
.
Gastroenterology
vol.
158
,
(
1
)
189
-
199
.
Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H et al.
(
2019
)
.
Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial
.
Gastroenterology
D'Haens GR, Lindsay JO, Loftus EV, Zhou W, Cataldi F, Xie W, Pugatch D, Panaccione R
(
2019
)
.
678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE
.
The American Journal of Gastroenterology
.
vol.
114
,
s399
-
s399
.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE et al.
(
2019
)
.
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
.
Gut
vol.
68
,
(
Suppl 3
)
s1
-
s106
.
Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al.
(
2019
)
.
PTH-084 Ustekinumab: Early experience and medium-term outcomes from a UK multi-centre real-world cohort
.
Gut
.
Conference:
Posters
vol.
68
,
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E et al.
(
2019
)
.
Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study
.
BMC Gastroenterology
vol.
19
,
(
1
)
Czuber‐Dochan W, Morgan M, Hughes LD, Lomer MCE, Lindsay JO, Whelan K
(
2019
)
.
Perceptions and psychosocial impact of food, nutrition, eating and drinking in people with inflammatory bowel disease: a qualitative investigation of food‐related quality of life
.
Journal of Human Nutrition and Dietetics
vol.
33
,
(
1
)
115
-
127
.
Honap S, Gadhok R, Rao R, Samaan MA, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al.
(
2019
)
.
Mo1917 – Ustekinumab: Early Experience and Medium-Term Outcomes from a Uk Multi-Centre Real-World Cohort
.
Gastroenterology
vol.
156
,
(
6
)
D’Haens GRAM, Lindsay JO, Panaccione R, Schreiber S
(
2019
)
.
Ulcerative Colitis: Shifting Sands
.
Drugs in R&D
vol.
19
,
(
2
)
227
-
234
.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel J-F, Cornillie F, Flynn HA, Huyck S et al.
(
2019
)
.
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
.
Journal of Crohn's and Colitis
vol.
13
,
(
9
)
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R et al.
(
2019
)
.
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
.
The Lancet Gastroenterology & Hepatology
vol.
4
,
(
5
)
341
-
353
.
Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC et al.
(
2019
)
.
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
.
JAMA
vol.
321
,
(
8
)
773
-
785
.
Lewis A, Nijhuis A, Berti G, Felice C, Jeffrey R, Iqbal S, Pomeranc AB, Aldelemi S et al.
(
2019
)
.
DOP20 Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease
.
Journal of Crohn's and Colitis
vol.
13
,
(
Supplement_1
)
s037
-
s038
.
Sandborn WJ, Schreiber S, Lee SD, Lindsay JO, Hebuterne X, Zhou W, Cataldi F, Lacerda AP et al.
(
2019
)
.
OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study
.
Journal of Crohn's and Colitis
.
vol.
13
,
s009
-
s009
.
Lewis A, Jeffrey R, Kumagai T, Hawkey CJ, Clark MM, Allez M, Satsangi J, Rogler G et al.
(
2019
)
.
OP20 Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
.
Journal of Crohn's and Colitis
.
vol.
13
,
s014
-
s014
.
Harrow P, Datta R, Stagg A, Lindsay JO
(
2019
)
.
P012 IL22 expression in intestinal immune cells is not augmented by AHR activation in health or Crohn’s disease
.
Journal of Crohn's and Colitis
.
vol.
13
,
s092
-
s092
.
Hornsby E, Peiris M, Peiris M, King HW, Wing ES, Lindsay JO, Blackshaw LA, Stagg AJ
(
2019
)
.
P016 Constitutive activity of the cation channel TRPM8 regulates monocyte to macrophage transition in humans to control intestinal inflammation
.
Journal of Crohn's and Colitis
.
vol.
13
,
s094
-
s094
.
Lewis A, Nijhuis A, Berti G, Bishop CL, Feakins R, Lindsay JO, Silver A
(
2019
)
.
P035 Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease
.
Journal of Crohn's and Colitis
.
vol.
13
,
s103
-
s104
.
Hoti I, McCarthy N, Giles E, Ayada I, Harrow P, Gordon H, Stagg A, Lindsay J
(
2019
)
.
P092 Circulating classical monocytes and intestinal macrophages exhibit reduced response to IL-10 in IBD
.
Journal of Crohn's and Colitis
.
vol.
13
,
s131
-
s132
.
Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al.
(
2019
)
.
P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort
.
Journal of Crohn's and Colitis
.
vol.
13
,
s260
-
s260
.
Rao R, Gadhok R, Whitley L, Burgess N, Amon P, Naik S, Lindsay J, McCartney S et al.
(
2019
)
.
P616 Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres
.
Journal of Crohn's and Colitis
.
vol.
13
,
s424
-
s425
.
Kok K, Ibarra A, Lindsay J
(
2019
)
.
New Therapeutic Strategies
.
Inflammatory Bowel Disease Nursing Manual
,
Springer Nature
Lewis A, Nijhuis A, Berti G, Felice C, Jeffrey R, Iqbal S, Pomeranc AB, Aldelemi S et al.
(
2019
)
.
Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn's disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
13
,
S38
-
S38
.
Honap S, Gadhok R, Rao R, Samaan MA, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al.
(
2019
)
.
USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES FROM A UK MULTI-CENTRE REAL-WORLD COHORT
.
GASTROENTEROLOGY
.
vol.
156
,
S885
-
S886
.
Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al.
(
2018
)
.
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
.
Journal of Crohn's and Colitis
vol.
13
,
(
1
)
139
-
140
.
Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Biancheri P, Di Sabatino A, Feakins R, Silver A et al.
(
2018
)
.
Epithelial down‐regulation of the miR‐200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition
.
Journal of Cellular and Molecular Medicine
vol.
22
,
(
11
)
5617
-
5628
.
Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA, Lindsay JO
(
2018
)
.
Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist
.
Clinical Medicine
vol.
18
,
(
4
)
329
-
334
.
Baker A-M, Cross W, Curtius K, Al Bakir I, Choi C-HR, Davis HL, Temko D, Biswas S et al.
(
2018
)
.
Evolutionary history of human colitis-associated colorectal cancer
.
Gut
vol.
68
,
(
6
)
Alexander T, Farge D, Badoglio M, Lindsay JO, Muraro PA, Snowden JA, Transplantation ADWPOTESFBAM
(
2018
)
.
Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms
.
Journal of Autoimmunity
vol.
92
,
35
-
46
.
Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al.
(
2018
)
.
ADWE-09 Low fodmap diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria in quiescent inflammatory bowel disease
.
Gut
.
Conference:
Small Bowel & Nutrition
vol.
67
,
Czuber-Dochan W, Morgan M, Lomer M, Lindsay J, Robert G, Whelan K
(
2018
)
.
OWE-037 Managing issues with food-related quality of life in inflammatory bowel disease – a qualitative study
.
Gut
.
Conference:
Small Bowel & Nutrition
vol.
67
,
Cox SR, Stagg AJ, Fromentin S, Ehrlich SD, McCarthy NE, Galleron N, Levenez F, Lomer M et al.
(
2018
)
.
902 - Low Fodmap Diet Improves Functional-Like Gastrointestinal Symptoms but Reduces Bifidobacteria and Faecalibacterium Prausnitzii in Quiescent Inflammatory Bowel Disease: A Randomised Controlled Trial and Metagenomic Analysis
.
Gastroenterology
vol.
154
,
(
6
)
s
-
177
.
Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L et al.
(
2018
)
.
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
.
Gastrointestinal Endoscopy
vol.
88
,
(
2
)
360
-
369.e2
.
Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA
(
2018
)
.
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators
.
Front Immunol
vol.
9
,
646
-
646
.
Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al.
(
2018
)
.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
.
Inflammatory Bowel Diseases
vol.
24
,
(
4
)
714
-
724
.
Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S et al.
(
2018
)
.
Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey
.
Journal of Crohn's and Colitis
vol.
12
,
(
5
)
600
-
609
.
Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G et al.
(
2018
)
.
DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
.
Journal of Crohn's and Colitis
vol.
12
,
(
suppl_1
)
s32
-
s32
.
Harrow P, McCarthy N, Stagg A, Lindsay J
(
2018
)
.
DOP017 Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s disease
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s41
-
s41
.
Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Tsilkos K et al.
(
2018
)
.
DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s49
-
s49
.
Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al.
(
2018
)
.
DOP057 ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: Summary of the ECCO-EBMT joint review
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s70
-
s71
.
Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al.
(
2018
)
.
DOP086 Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent inflammatory bowel disease: a randomised controlled trial and metagenomic analysis
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s87
-
s87
.
Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Feakins R, Silver A, Lindsay JO
(
2018
)
.
P002 Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 family
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s91
-
s92
.
Gordon H, Gadhok R, Ibarra A, Lindsay JO
(
2018
)
.
P689 UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
.
Journal of Crohn's and Colitis
vol.
12
,
(
supplement_1
)
s459
-
s459
.
Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al.
(
2018
)
.
Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn’s Disease: A Review on Behalf of ECCO and EBMT
.
Journal of Crohn's and Colitis
vol.
12
,
(
4
)
476
-
488
.
Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al.
(
2018
)
.
ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S70
-
S71
.
Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Tsilkos K et al.
(
2018
)
.
Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S49
-
S49
.
Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Feakins R, Silver A, Lindsay JO
(
2018
)
.
Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn's disease and is associated with down regulation of the miR-200 family
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S91
-
S92
.
Lindsay JO, Woodland P
(
2018
)
.
Gastrointestinal endoscopy
.
Edition
,
Cox SR, Stagg AJ, Fromentin S, Ehrlich SD, McCarthy NE, Galleron N, Levenez F, Lomer M et al.
(
2018
)
.
LOW FODMAP DIET IMPROVES FUNCTIONAL-LIKE GASTROINTESTINAL SYMPTOMS BUT REDUCES BIFIDOBACTERIA AND FAECALIBACTERIUM PRAUSNITZII IN QUIESCENT INFLAMMATORY BOWEL DISEASE: A RANDOMISED CONTROLLED TRIAL AND METAGENOMIC ANALYSIS
.
GASTROENTEROLOGY
.
vol.
154
,
S177
-
S177
.
Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G et al.
(
2018
)
.
Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S32
-
S32
.
Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al.
(
2018
)
.
Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent inflammatory bowel disease: a randomised controlled trial and metagenomic analysis
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S87
-
S87
.
Czuber-Dochan W, Morgan M, Lomer M, Lindsay J, Robert G, Whelan K
(
2018
)
.
MANAGING ISSUES WITH FOOD-RELATED QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE - A QUALITATIVE STUDY
.
GUT
.
vol.
67
,
A162
-
A162
.
Gordon H, Gadhok R, Ibarra A, Lindsay JO
(
2018
)
.
UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
.
JOURNAL OF CROHNS & COLITIS
.
vol.
12
,
S459
-
S459
.
Rigoni A, Poulsom R, Jeffery R, Mehta S, Lewis A, Yau C, Giannoulatou E, Feakins R et al.
(
2017
)
.
Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans
.
Inflamm Bowel Dis
vol.
24
,
(
1
)
136
-
148
.
Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K
(
2017
)
.
Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial
.
Proceedings of The Nutrition Society
.
vol.
76
,
Ball JA, Clear AJ, Calaminici M, Stagg A, Lindsay J, Gribben JG, Davies J
(
2017
)
.
Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions
.
Blood
.
vol.
130
,
Rossi M, Aggio R, Staudacher HM, Lomer MC, Lindsay JO, Irving P, Probert C, Whelan K
(
2017
)
.
Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome
.
Clinical Gastroenterology and Hepatology
vol.
16
,
(
3
)
385
-
391.e1
.
Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al.
(
2017
)
.
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
.
Journal of Crohn's and Colitis
vol.
12
,
(
2
)
145
-
156
.
Cooper J, Blake I, Lindsay JO, Hawkey CJ
(
2017
)
.
Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study)
.
BMJ Open
vol.
7
,
(
9
)
Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H
(
2017
)
.
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease
.
Digestive and Liver Disease
vol.
49
,
(
10
)
1086
-
1091
.
Panés J, Rubin D, Vermeire S, Lindsay J, Sands B, Su C, Friedman G, Zhang H et al.
(
2017
)
.
AODWE-004 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
.
Gut
.
Conference:
Inflammatory Bowel Disease
vol.
66
,
Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM et al.
(
2017
)
.
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial
.
Gastroenterology
vol.
153
,
(
4
)
936
-
947
.
Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K
(
2017
)
.
Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial
.
Journal of Crohn's and Colitis
vol.
11
,
(
12
)
1420
-
1429
.
Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al.
(
2017
)
.
Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial
.
The Lancet Gastroenterology & Hepatology
vol.
2
,
(
6
)
399
-
406
.
Lindsay JO
(
2017
)
.
Autologous Stem Cell Transplantation for Refractory Crohn’s Disease
.
Journal of Crohn's and Colitis
vol.
11
,
(
10
)
1157
-
1158
.
Gordon H, Gadhok R, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper BE, Lindsay JO
(
2017
)
.
Sa1833 Anti-TNFS More Frequently Stopped Due to Loss of Response in British Asians with Crohn's Disease: A Single Centre Retrospective Analysis
.
Gastroenterology
.
vol.
152
,
Gordon H, Hoti I, Lindsay JO, Stagg AJ
(
2017
)
.
Tu1908 Circulating Non-Classical Monocytes are Reduced in Patients with Active IBD but Increase after Vedolizumab: A Role for α4β7 in Myeloid Cell Recruitment to the Inflamed Intestine
.
Gastroenterology
.
vol.
152
,
s1003
-
s1004
.
MCCARTHY NE, Tyler CJ, Lindsay JO, Stagg AJ, Moser B, Eberl M
(
2017
)
.
Antigen-presenting human γδ T-cells promote intestinal CD4+ T-cell expression of IL-22 and mucosal release of calprotectin
.
Journal of Immunology
Lewis A, Felice C, Kumagai T, Lai C, Singh K, Jeffery RR, Feakins R, Giannoulatou E et al.
(
2017
)
.
The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients
.
PLoS One
vol.
12
,
(
3
)
e0173664
-
e0173664
.
Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT et al.
(
2017
)
.
UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
.
Gut
vol.
66
,
(
6
)
Nijhuis A, Curciarello R, Mehta S, Feakins R, Bishop CL, Lindsay JO, Silver A
(
2017
)
.
MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8
.
Cell Tissue Res
Hedin CR, van der Gast CJ, Stagg AJ, Lindsay JO, Whelan K
(
2017
)
.
The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease
.
Gut Microbes
vol.
8
,
(
4
)
359
-
365
.
van Rheenen PF, Aloi M, Biron IA, Carlsen K, Cooney R, Cucchiara S, Cullen G, Escher JC et al.
(
2017
)
.
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
.
Journal of Crohn's and Colitis
vol.
11
,
(
9
)
1032
-
1038
.
Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D
(
2017
)
.
MMP-12, a novel mediator of nociception in Crohn's disease
.
JOURNAL OF CROHNS & COLITIS
.
Conference:
European Crohn's and Colitis (ECCO) Congress 2017
vol.
11
,
S120
-
S120
.
Gisbert JP, Patel H, Nguyen G, Bokemeyer B, Armuzzi A, Lindsay J, Khalid J, Peyrin-Biroulet L
(
2017
)
.
P-061 Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review
.
Inflammatory Bowel Diseases
vol.
23
,
(
suppl_1
)
s25
-
s25
.
Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D
(
2017
)
.
P086 MMP-12, a novel mediator of nociception in Crohn's disease
.
J Crohns Colitis
.
vol.
11
,
S120
-
S120
.
Hoti I, McCarthy NE, Giles EM, Ayada I, Gordon H, Stagg AJ, Lindsay JO
(
2017
)
.
TNF alpha production by classical monocytes is poorly controlled by IL-10 in patients with IBD
.
JOURNAL OF CROHNS & COLITIS
.
Conference:
12th Congress of ECCO - European Crohn's and Colitis Organisation
(
Barcelona, Spain
)
from:
18/02/2017
to:
15/02/2017
,
vol.
11
,
S112
-
S112
.
Lindsay JO, Irving PM, Mantzaris GJ, Panés J, Board OBOEECAEG
(
2017
)
.
ECCO IBD Curriculum
.
Journal of Crohn's and Colitis
vol.
11
,
(
9
)
1039
-
1043
.
Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al.
(
2017
)
.
OP004 Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
.
Journal of Crohn's and Colitis
vol.
11
,
(
suppl_1
)
s2
-
s3
.
Gordon H, Hoti I, Lindsay JO, Stagg A
(
2017
)
.
P053 Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine
.
Journal of Crohn's and Colitis
vol.
11
,
(
suppl_1
)
s104
-
s105
.
McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J
(
2017
)
.
P059 Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease
.
Journal of Crohn's and Colitis
.
vol.
11
,
s107
-
s107
.
Panés J, Rubin DT, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H et al.
(
2017
)
.
P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
.
Journal of Crohn's and Colitis
vol.
11
,
(
suppl_1
)
s315
-
s317
.
Rubin DT, Panés J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al.
(
2017
)
.
P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis
.
Journal of Crohn's and Colitis
vol.
11
,
(
suppl_1
)
s364
-
s365
.
Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO
(
2017
)
.
P614 Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
.
Journal of Crohn's and Colitis
vol.
11
,
(
suppl_1
)
s393
-
s393
.
Brooks AJ, Smith PJ, Lindsay JO
(
2017
)
.
Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare
.
Frontline Gastroenterology
vol.
9
,
(
1
)
Yarlas A, Sands BE, Rubin DT, Lindsay J, Panes J, Vermeire S, Chen LA, Bayliss M et al.
(
2017
)
.
A SYSTEMATIC REVIEW OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE FOR MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS
.
VALUE IN HEALTH
.
vol.
20
,
A185
-
A185
.
Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO
(
2017
)
.
ANTI-TNFS MORE FREQUENTLY STOPPED DUE TO LOSS OF RESPONSE IN BRITISH ASIANS WITH CROHN'S DISEASE: A SINGLE CENTRE RETROSPECTIVE ANALYSIS
.
GUT
.
vol.
66
,
A255
-
A255
.
Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO
(
2017
)
.
Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S393
-
S393
.
Gordon H, Hoti I, Lindsay JO, Stagg A
(
2017
)
.
Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S104
-
S105
.
Lewis A, Felice C, Nihjuis A, Iqbal S, Mehta S, Feakins R, Armuzzi A, Silver A et al.
(
2017
)
.
Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S17
-
S17
.
Perez Gisbert J, Patel H, Nguyen G, Bokemeyer B, Armuzzi A, Lindsay J, Khalid J, Peyrin-Biroule L
(
2017
)
.
Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review
.
INFLAMMATORY BOWEL DISEASES
.
vol.
23
,
S25
-
S25
.
Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H
(
2017
)
.
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease
.
DIGESTIVE AND LIVER DISEASE
vol.
49
,
(
10
)
1086
-
1091
.
McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J
(
2017
)
.
Mucosal inflammation promotes activation of circulating Vd2+T-cells in Crohn's disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S107
-
S107
.
Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al.
(
2017
)
.
Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S2
-
S3
.
McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S
(
2017
)
.
Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S356
-
S357
.
Rubin DT, Panes J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al.
(
2017
)
.
The SF-36r\® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S364
-
S365
.
McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S
(
2017
)
.
The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
.
JOURNAL OF CROHNS & COLITIS
.
vol.
11
,
S261
-
S262
.
Khalid JM, Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen G, Bokemeyer B, Lindsay J, Smyth M et al.
(
2016
)
.
Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease
.
The American Journal of Gastroenterology
.
vol.
111
,
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ et al.
(
2016
)
.
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
.
Journal of Crohn's and Colitis
vol.
11
,
(
1
)
3
-
25
.
Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J et al.
(
2016
)
.
Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
.
The Lancet Gastroenterology & Hepatology
vol.
1
,
(
4
)
273
-
282
.
Lindsay J, Gisbert J, Mody R, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen G, Siebenaler J et al.
(
2016
)
.
PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists
.
Gut
.
vol.
65
,
Armuzzi A, Lindsay J, Mody R, Bokemeyer B, Gisbert J, Peyrin-Biroulet L, Nguyen G, Siebenaler J et al.
(
2016
)
.
PTH-071 Indicators of Suboptimal Therapy Among Crohn’s Disease Patients Treated with Tumour Necrosis Factor Antagonists: Results from A Multi-National Study
.
Gut
.
vol.
65
,
Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J
(
2016
)
.
PTU-068 Dose Optimisation Using Drug and Antibody Levels Can Benefit 50% Patients Prescribed Anti TNF Therapy Compared to Empiric Dose Adjustment
.
Gut
.
vol.
65
,
Peyrin‐Biroulet L, Germain A, Patel AS, Lindsay JO
(
2016
)
.
Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitis
.
Alimentary Pharmacology & Therapeutics
vol.
44
,
(
8
)
807
-
816
.
Walton S-J, Lewis A, Jeffery R, Thompson H, Feakins R, Giannoulatou E, Yau C, Lindsay JO et al.
(
2016
)
.
Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours
.
Oncoscience
vol.
3
,
(
5-6
)
173
-
185
.
Hawkey CJ, Lindsay J, Gribben J
(
2016
)
.
Stem Cell Transplantation for Refractory Crohn Disease—Reply
.
JAMA
vol.
315
,
(
23
)
2620
-
2621
.
Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Van Assche G, Lee JC et al.
(
2016
)
.
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
.
Journal of Crohn's and Colitis
vol.
10
,
(
12
)
1385
-
1394
.
Giles EM, Sanders TJ, McCarthy NE, Lung J, Pathak M, MacDonald TT, Lindsay JO, Stagg AJ
(
2016
)
.
Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease
.
Mucosal Immunology
vol.
10
,
(
1
)
184
-
193
.
Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS et al.
(
2016
)
.
Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
.
Alimentary Pharmacology & Therapeutics
vol.
43
,
(
8
)
910
-
923
.
Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J
(
2016
)
.
Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment
.
JOURNAL OF CROHNS & COLITIS
.
vol.
10
,
S71
-
S72
.
Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K
(
2016
)
.
Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent inflammatory bowel disease: a double-blind, placebo-controlled, randomised, cross-over re-challenge trial
.
JOURNAL OF CROHNS & COLITIS
.
vol.
10
,
S342
-
S342
.
Tyler C, McCarthy N, Moser B, Stagg A, Eberl M, Lindsay J
(
2016
)
.
Human intestinal Vδ2+T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
.
JOURNAL OF CROHNS & COLITIS
vol.
10
,
S29
-
S29
.
Lindsay J, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al.
(
2016
)
.
Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn's disease: pooled results from the ASTIC trial
.
JOURNAL OF CROHNS & COLITIS
.
vol.
10
,
S37
-
S38
.
Arnott I, Mowat C, Ennis H, Keerie C, Lewis S, Kennedy N, Cahill A, Morris A et al.
(
2016
)
.
The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients
.
JOURNAL OF CROHNS & COLITIS
.
vol.
10
,
S21
-
S22
.
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M et al.
(
2015
)
.
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial
.
JAMA
vol.
314
,
(
23
)
2524
-
2534
.
Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K
(
2015
)
.
Food-related Quality of Life in Inflammatory Bowel Disease: Development and Validation of a Questionnaire
.
Journal of Crohn's and Colitis
vol.
10
,
(
2
)
194
-
201
.
Anderson JL, Hedin CR, Benjamin JL, Koutsoumpas A, Ng SC, Hart AL, Forbes A, Stagg AJ et al.
(
2015
)
.
Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case–control study
.
Journal of Crohn's and Colitis
vol.
9
,
(
11
)
1024
-
1031
.
McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM et al.
(
2015
)
.
Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn’s disease
.
Journal of Clinical Investigation
vol.
125
,
(
8
)
3215
-
3225
.
Kennedy N, Lindsay J, Gordon J, Hart A, McCartney S, Irving P, Satsangi J, Lees C
(
2015
)
.
OC-009 Withdrawal of anti-tnf following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis
.
Gut
.
vol.
64
,
Parisinos C, Ooi J, Lindsay J, Parkes G
(
2015
)
.
OC-034 Probiotics for the prevention of antibiotic associated diarrhoea in the older inpatient population; a systematic review and meta-analysis
.
Gut
.
vol.
64
,
Staudacher H, Lomer M, Lindsay J, Irving P, Whelan K
(
2015
)
.
OC-103 The impact of low fodmap dietary advice and probiotics on symptoms in irritable bowel syndrome: a randomised, placebo-controlled, 2 × 2 factorial trial
.
Gut
.
vol.
64
,
Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al.
(
2015
)
.
PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
.
Gut
.
vol.
64
,
Tandiari T, Ibarra A, Younge L, Allepuz AP, Thompson A, Meade U, Arkir Z, Giles E et al.
(
2015
)
.
PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice
.
Gut
.
vol.
64
,
Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al.
(
2015
)
.
PTU-082 Responders to haemopoietic stem cell transplantation for crohn’s disease
.
Gut
.
vol.
64
,
Sharratt C, Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G et al.
(
2015
)
.
PTU-083 Substantial histological improvement following haemopoetic stem cell transplantation
.
Gut
.
vol.
64
,
Mehta S, Nijhuis A, Kumagai T, Lindsay J, Silver A
(
2015
)
.
Defects in the adherens junction complex (E-cadherin/ β-catenin) in inflammatory bowel disease
.
Cell Tissue Res
vol.
360
,
(
3
)
749
-
760
.
Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-Biroulet L
(
2015
)
.
Systematic review: The financial burden of surgical complications in patients with ulcerative colitis
.
Alimentary Pharmacology and Therapeutics
vol.
41
,
(
11
)
1066
-
1078
.
Lewis A, Mehta S, Hanna LN, Rogalski LA, Jeffery R, Nijhuis A, Kumagai T, Biancheri P et al.
(
2015
)
.
Low Serum Levels of MicroRNA-19 Are Associated with a Stricturing Crohn's Disease Phenotype
.
Inflammatory Bowel Diseases
vol.
21
,
(
8
)
1926
-
1934
.
Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin‐Biroulet L
(
2015
)
.
Systematic review: the financial burden of surgical complications in patients with ulcerative colitis
.
Alimentary Pharmacology & Therapeutics
vol.
41
,
(
11
)
1066
-
1078
.
Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K
(
2015
)
.
Siblings of patients with Crohn’s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities
.
Gut
vol.
65
,
(
6
)
Biancheri P, Di Sabatino A, Curciarello R, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT
(
2015
)
.
Mo1724 Interleukin-17A Homodimer Reduces Pro-Inflammatory Cytokine Production by Inflammatory Bowel Disease Mucosa Cultured Ex Vivo
.
Gastroenterology
vol.
148
,
(
4
)
s
-
695
.
van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F et al.
(
2015
)
.
Segundo consenso europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Parte 3: situaciones especiales (versión española)
.
Revista de Gastroenterología de México
vol.
80
,
(
1
)
74
-
106
.
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, d’Haens G, d’Hoore A et al.
(
2015
)
.
Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española)
.
Revista de Gastroenterología de México
vol.
80
,
(
1
)
32
-
73
.
Alexakis C, Nash A, Lloyd M, Brooks F, Lindsay JO, Poullis A
(
2015
)
.
Inflammatory bowel disease in young patients: challenges faced by black and minority ethnic communities in the UK
.
Health & Social Care in the Community
vol.
23
,
(
6
)
665
-
672
.
Lewis A, Nijhuis A, Mehta S, Kumagai T, Feakins R, Lindsay JO, Silver A
(
2015
)
.
Intestinal Fibrosis in Crohn's Disease: Role of microRNAs as Fibrogenic Modulators, Serum Biomarkers, and Therapeutic Targets
.
Inflammatory Bowel Diseases
vol.
21
,
(
5
)
1141
-
1150
.
Kennedy NA, Warner B, Johnston E, Flanders L, Hendy P, Ding N, Harris R, Fadra AS et al.
(
2015
)
.
Anti-TNF withdrawal in IBD: Relapse and recapture rates and predictive factors from 160 patients in a pan-UK study
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S41
-
S42
.
Younge L, Lindsay J, Langmead L, Czuber-Dochan W
(
2015
)
.
Assessing the satisfaction levels of older patients with different types of follow-up care for inflammatory bowel disease
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S444
-
S445
.
Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al.
(
2015
)
.
Cannabidiol for symptomatic treatment of ulcerative colitis: Results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S287
-
S287
.
Peyrin-Biroulet L, Patel AS, Lindsay JO
(
2015
)
.
Colectomy is not a cure for ulcerative colitis: A systematic review
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S280
-
S281
.
Biancheri P, Di Sabatino A, Curciarello R, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT
(
2015
)
.
Interleukin-17A Homodimer Reduces Pro-Inflammatory Cytokine Production by Inflammatory Bowel Disease Mucosa Cultured <i>Ex Vivo</i>
.
GASTROENTEROLOGY
.
vol.
148
,
S695
-
S695
.
Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al.
(
2015
)
.
Prolonged Deep Remission of Ileocolonic Crohn's Disease following Autologous Haemopoetic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S11
-
S12
.
Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A
(
2015
)
.
Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases
.
Aliment Pharmacol Ther
vol.
41
,
(
1
)
26
-
38
.
Lindsay JO, Peyrin-Biroulet L, Patel AS, Bergman A
(
2015
)
.
Systematic review: The financial burden of surgical complications in patients with ulcerative colitis
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S232
-
S233
.
Parisinos CA, Harrow P, Langmead L, van Heel DA, Lindsay JO
(
2015
)
.
eHealth optimises documentation and enables live access to IBD Multi Disciplinary Team outcomes
.
JOURNAL OF CROHNS & COLITIS
vol.
9
,
S366
-
S367
.
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W et al.
(
2014
)
.
Segundo Consenso Europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática Parte 1: Definiciones y diagnóstico (versión española)
.
Revista de Gastroenterología de México
vol.
79
,
(
4
)
263
-
289
.
Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H et al.
(
2014
)
.
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
.
Alimentary Pharmacology & Therapeutics
vol.
40
,
(
11-12
)
1313
-
1323
.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al.
(
2014
)
.
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
.
Nat Genet
vol.
46
,
(
10
)
1131
-
1134
.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al.
(
2014
)
.
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
.
Nature Genetics
vol.
46
,
(
10
)
1131
-
1134
.
(
2014
)
.
Psychological Aspects of Inflammatory Bowel Disease, A biopsychosocial approach
.
Taylor & Francis
Nijhuis A, Biancheri P, Lewis A, Bishop CL, Giuffrida P, Chan C, Feakins R, Poulsom R et al.
(
2014
)
.
In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts
.
Clin Sci (Lond)
vol.
127
,
(
5
)
341
-
350
.
Parkes GC, Whelan K, Lindsay JO
(
2014
)
.
Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect
.
Journal of Crohn's and Colitis
vol.
8
,
(
8
)
717
-
725
.
Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO
(
2014
)
.
Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease
.
Frontline Gastroenterology
vol.
6
,
(
1
)
Heap G, Singh A, Bewshea C, Weedon M, Cole A, Creed T, Greig E, Irving P et al.
(
2014
)
.
OC-004 Thiopurine Induced Pancreatitis In Inflammatory Bowel Disease: Clinical Features And Genetic Determinants
.
Gut
vol.
63 Suppl 1
,
A2
-
A3
.
Hedin C, van der Gast C, Rogers G, McCartney S, Stagg A, Lindsay J, Whelan K
(
2014
)
.
OC-051 Siblings Of Crohn's Disease Patients Exhibit A Biologically Relevant Dysbiosis In The Mucosal Microbial Community: A 16s Rrna Gene Pyrosequencing Study
.
Gut
vol.
63 Suppl 1
,
Hughes L, Lindsay J, Lomer M, Ayis S, King L, Morgan M, Whelan K
(
2014
)
.
PTU-102 Development Of A Food Related Quality Of Life Questionnaire For People With Ibd
.
Gut
vol.
63 Suppl 1
,
Russo E, Hackett R, Campbell S, Lindsay J, Irving P, Orchard T
(
2014
)
.
PWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn's Disease
.
Gut
vol.
63 Suppl 1
,
A154
-
A155
.
Biancheri P, Di Sabatino A, Curciarello R, Corazza G, Lindsay J, MacDonald T
(
2014
)
.
PWE-087 Interleukin-17a Homodimer Reduces Pro-inflammatory Cytokine Production By Inflammatory Bowel Disease Mucosa Cultured Ex Vivo
.
Gut
vol.
63 Suppl 1
,
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al.
(
2014
)
.
6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants
.
Gastroenterology
vol.
146
,
(
5
)
s
-
2
.
Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ
(
2014
)
.
Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn's disease
.
Gastroenterology
vol.
146
,
(
5
)
Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, Thomas M, Lindsay JO, Stagg AJ
(
2014
)
.
Sa1778 Constitutive Type I Interferon, via STAT1 Activation, Selectively Promotes Regulatory T Cell Function in the Healthy Human Intestine, but Not in Inflammatory Bowel Disease
.
Gastroenterology
.
vol.
146
,
MacFie TS, Poulsom R, Parker A, Warnes G, Boitsova T, Nijhuis A, Suraweera N, Poehlmann A et al.
(
2014
)
.
DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid
.
Inflamm Bowel Dis
vol.
20
,
(
3
)
514
-
524
.
Hedin C, van der Gast C, Rogers G, McCartney S, Stagg AJ, Lindsay JO, Whelan K
(
2014
)
.
OP020 16S rRNA gene pyrosequencing indicate that siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities
.
Journal of Crohn's and Colitis
vol.
8
,
(
Supplement_1
)
s11
-
s12
.
Biancheri P, Di Sabatino A, Curciarello R, Giuffrida P, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT
(
2014
)
.
P053 Interleukin-17A homodimer reduces pro-inflammatory cytokine production by inflammatory bowel disease mucosa cultured ex vivo
.
Journal of Crohn's and Colitis
vol.
8
,
(
Supplement_1
)
s85
-
s85
.
Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T et al.
(
2014
)
.
Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings
.
Gut
McCarthy NE, Hedin CR, Sanders TJ, Amon P, Baji V, Giles EM, Wildemann M, Bashir Z et al.
(
2014
)
.
Colonic Vδ2+T-cells display elevated TNF production and reversible ablation by azathioprine therapy in Crohn's disease
.
IMMUNOLOGY
.
vol.
143
,
165
-
165
.
Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, Thomas M, Lindsay JO, Stagg AJ
(
2014
)
.
Constitutive Type I Interferon, via STAT1 Activation, Selectively Promotes Regulatory T Cell Function in the Healthy Human Intestine, but Not in Inflammatory Bowel Disease
.
GASTROENTEROLOGY
.
vol.
146
,
S293
-
S294
.
Giles E, Sanders TJ, McCarthy NE, Sanderson I, Lindsay J, MacDonald TT, Stagg AJ
(
2014
)
.
Constitutive Type I Interferon, via STAT1 activation, selectively promotes regulatory T cell function in the healthy human intestine, but not in IBD
.
IMMUNOLOGY
.
vol.
143
,
17
-
17
.
Parkes GC, Whelan K, Lindsay JO
(
2014
)
.
Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect
.
Journal of Crohn's and Colitis
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al.
(
2014
)
.
Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants
.
GASTROENTEROLOGY
.
vol.
146
,
S2
-
S2
.
Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO
(
2013
)
.
Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial
.
Lancet
vol.
382
,
(
9910
)
2084
-
2092
.
Goodhand JR, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury FA, Croft NM et al.
(
2013
)
.
Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease
.
Aliment Pharmacol Ther
vol.
38
,
(
9
)
1097
-
1108
.
Allison M, Lindsay J, Gould D, Kelly D
(
2013
)
.
Surgery in young adults with inflammatory bowel disease: a narrative account
.
Int J Nurs Stud
vol.
50
,
(
11
)
1566
-
1575
.
McCarthy NE, Bashir Z, Vossenkämper A, Hedin CR, Giles EM, Bhattacharjee S, Brown SG, Sanders TJ et al.
(
2013
)
.
Proinflammatory Vδ2+ T cells populate the human intestinal mucosa and enhance IFN-γ production by colonic αβ T cells
.
J Immunol
vol.
191
,
(
5
)
2752
-
2763
.
Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T, INDIGO study investigators
(
2013
)
.
A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
.
Aliment Pharmacol Ther
vol.
38
,
(
1
)
52
-
61
.
Mehta SJ, Silver AR, Lindsay JO
(
2013
)
.
Review article: strategies for the management of chronic unremitting ulcerative colitis
.
Aliment Pharmacol Ther
vol.
38
,
(
2
)
77
-
97
.
Hawkey C, Allez M, Ardizzone S, Clark L, Columbel J-F, Danese S, Farge-Bancel D, Labopin M et al.
(
2013
)
.
OC-014 Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn’S Disease
.
Gut
vol.
62
,
(
Suppl 1
)
Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott N, Murrells T et al.
(
2013
)
.
OC-017 A Discriminant Analysis Demonstrates that Siblings of Patients with Crohn’S Disease have a Distinct Microbiological and Immune Phenotype Compared with Healthy Controls: Insights into Disease Pathogenesis
.
Gut
vol.
62
,
(
Suppl 1
)
Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott NJ, Murrells T et al.
(
2013
)
.
260 Siblings of Patients With Crohn's Disease Have a Distinct Microbiological and Immune Phenotype Compared to Healthy Controls: Insights Into Disease Pathogenesis
.
Gastroenterology
vol.
144
,
(
5
)
Landy J, Wahed M, Peake STC, Hussein M, Ng SC, Lindsay JO, Hart AL
(
2013
)
.
Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres
.
Journal of Crohn's and Colitis
vol.
7
,
(
11
)
Biancheri P, Di Sabatino A, Nijhuis A, Lai C, Ghosh A, Macdonald TT, Lindsay J, Silver A et al.
(
2013
)
.
OC.07.1 MICRO-RNA EXPRESSION PROFILING IDENTIFIES MIR-29B AS A RELEVANT PRO-FIBROGENIC FACTOR IN CROHN'S DISEASE INTESTINAL STRICTURES
.
Digestive and Liver Disease
vol.
45
,
s70
-
s71
.
Biancheri P, Nijhuis A, Di Sabatino A, Lai C, Ghosh A, MacDonald TT, Corazza GR, Lindsay J et al.
(
2013
)
.
P057 Micro-RNA expression profiling identifies miR-29b as a relevant pro-fibrogenic factor in Crohn's disease intestinal strictures
.
Journal of Crohn's and Colitis
vol.
7
,
(
Supplement_1
)
s32
-
s32
.
McCarthy N, Hedin C, Bashir Z, Vossenkämper A, Giles E, Sanders T, Whelan K, MacDonald T et al.
(
2013
)
.
P066 Human intestinal Vδ2+ T-cells promote mucosal inflammation in Crohn's disease and are selectively ablated by azathioprine therapy
.
Journal of Crohn's and Colitis
vol.
7
,
(
Supplement_1
)
s35
-
s36
.
Goodhand J, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury F, Croft N et al.
(
2013
)
.
P335 Thiopurine nonadherence is more common in adolescents than adults with IBD, is associated with psychological distress and impacts on the management and prognosis
.
Journal of Crohn's and Colitis
.
vol.
7
,
s144
-
s144
.
Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F et al.
(
2013
)
.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations
.
Journal of Crohn's and Colitis
vol.
7
,
(
1
)
1
-
33
.
Andreyev HJ, Benton B, Lalji A, Pennert K, Lindsay JO, Gage H, Norton C
(
2013
)
.
ALGORITHMIC MANAGEMENT OF RADIATION-INDUCED GI SYMPTOMS IS HIGHLY EFFECTIVE: THE ORBIT RANDOMISED CONTROLLED TRIAL
.
GUT
.
vol.
62
,
A29
-
A30
.
Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO
(
2013
)
.
Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): A randomised controlled trial
.
The Lancet
vol.
382
,
(
9910
)
2084
-
2092
.
Hawkey C, Allez M, Ardizzone S, Clark E, Clark M, Colombel JF, Danese S, Farge-Bancel D et al.
(
2013
)
.
Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT
.
BONE MARROW TRANSPLANTATION
.
vol.
48
,
S44
-
S44
.
Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, MacDonald TT, Lindsay JO, Stagg AJ
(
2013
)
.
Constitutive Type I Interferon, via STAT1 activation, promotes regulatory T cell function in the healthy human intestine, but not in inflammatory bowel disease
.
IMMUNOLOGY
.
vol.
140
,
168
-
168
.
Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ
(
2013
)
.
Retinoic acid generation by human intestinal CD14<SUP>+</SUP> macrophages is enhanced in Crohn's disease and maintains an inflammatory phenotype
.
IMMUNOLOGY
.
vol.
140
,
32
-
32
.
Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott NJ, Murrells T et al.
(
2013
)
.
Siblings of Patients With Crohn's Disease Have a Distinct Microbiological and Immune Phenotype Compared to Healthy Controls: Insights Into Disease Pathogenesis
.
GASTROENTEROLOGY
.
vol.
144
,
S57
-
S58
.
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, D'Haens G, D'Hoore A et al.
(
2012
)
.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
.
Journal of Crohn's and Colitis
vol.
6
,
(
10
)
991
-
1030
.
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W et al.
(
2012
)
.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
.
Journal of Crohn's and Colitis
vol.
6
,
(
10
)
965
-
990
.
Kamperidis N, Goodhand JR, Chowdhury FA, Koodun Y, Direzke NC, Naik S, Sanderson IR, Croft NM et al.
(
2012
)
.
Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease
.
J Pediatr Gastroenterol Nutr
vol.
54
,
(
5
)
685
-
689
.
Biancheri P, Nijhuis A, Lai C, Ghosh A, Feakins R, Chan C, Di Sabatino A, Corazza GR et al.
(
2012
)
.
Tu1915 Differential MicroRNA Expression Profiles in Crohn's Disease Strictured Versus Non-Strictured Intestine
.
Gastroenterology
vol.
142
,
(
5
)
s
-
877
.
Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL et al.
(
2012
)
.
The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent
.
Aliment Pharmacol Ther
vol.
35
,
(
8
)
929
-
940
.
Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, Naik S, Croft NM et al.
(
2012
)
.
Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease
.
Inflamm Bowel Dis
vol.
18
,
(
3
)
513
-
519
.
Hedin CR, Stagg AJ, Whelan K, Lindsay JO
(
2012
)
.
Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention
.
Gut
vol.
61
,
(
2
)
311
-
318
.
Macfie T, Parker A, Nijhuis A, Boitsova T, Suraweera N, Jeffery R, Poulsom R, Lindsay J et al.
(
2012
)
.
5-ASA ENHANCES <i>DUOX2</i> EXPRESSION IN ACTIVE ULCERATIVE COLITIS: A RISK FOR COLORECTAL CANCER?
.
GUT
vol.
61
,
A401
-
A402
.
Tshuma N, Aboulela S, Chowdhury F, Macken L, Kamperidis N, Goodhand J, Lindsay J
(
2012
)
.
BSG information group symposium & free papers: "Social media and apps: new opportunities, new risks" CONTENT ANALYSIS OF ILLNESS BLOGS POSTED ONLINE BY PATIENTS WITH IBD
.
GUT
vol.
61
,
A68
-
A69
.
Biancheri P, Nijhuis A, Lai C, Ghosh A, Feakins R, Chan C, Di Sabatino A, Corazza GR et al.
(
2012
)
.
Differential MicroRNA Expression Profiles in Crohn's Disease Strictured Versus Non-Strictured Intestine
.
GASTROENTEROLOGY
.
vol.
142
,
S877
-
S877
.
McCarthy NE, Hedin CR, Vossenkaemper A, Bhattacharjee S, Brown SG, Sanders TJ, Giles EM, Whelan K et al.
(
2012
)
.
HUMAN ANTI-MICROBIAL Vδ2+T-CELLS ARE NOVEL INTESTINAL LYMPHOCYTES WITH FUNCTIONAL RELEVANCE IN CROHN'S DISEASE
.
GUT
.
vol.
61
,
A4
-
A4
.
Sanders TJ, McCarthy NE, Giles E, Lindsay JO, Stagg AJ
(
2012
)
.
INTESTINAL INFLAMMATION REGULATES RETINOIC ACID DEPENDENT IMPRINTING OF GUT TROPISM BY DENDRITIC CELLS INDEPENDENTLY OF RALDH EXPRESSION
.
GUT
.
vol.
61
,
A402
-
A402
.
Hedin CR, Taylor K, Louis P, Farquharson F, McCartney S, Prescott NJ, Stagg AJ, Lindsay JO et al.
(
2012
)
.
MICROBIAL, PHENOTYPIC AND GENETIC MARKERS OF RISK: ASPECTS OF CROHN'S DISEASE THAT ARE SHARED BY UNAFFECTED SIBLINGS
.
GUT
vol.
61
,
A22
-
A23
.
Nijhuis A, Biancheri P, Lai C, Ghosh A, Boitsova T, Chan C, MacDonald T, Lindsay J et al.
(
2012
)
.
MICRORNA EXPRESSION PROFILING IN STRICTURING CROHN'S DISEASE IDENTIFIES MIR-34A AS A FUNCTIONALLY RELEVANT INFLUENCE ON DISEASE PHENOTYPE
.
GUT
vol.
61
,
A167
-
A168
.
Andreyev HJ, Thomas K, Benton B, Lalji A, Lindsay JO, Gage H, Norton C
(
2012
)
.
OPTIMISING RADIATION BOWEL INJURY THERAPY, THE ORBIT STUDY, A RANDOMISED CONTROLLED TRIAL
.
GUT
vol.
61
,
A36
-
A36
.
Hedin CR, Louis P, Farquharson F, McCartney S, Stagg AJ, Lindsay JO, Whelan K
(
2012
)
.
PREBOTICS AS PRIMARY PREVENTION OF CROHN'S DISEASE: IMPACT ON LUMINAL MICROBIOLOGY AND ELEVATED FAECAL CALPROTECTIN IS GREATER IN HEALTHY SIBLINGS THAN IN PATIENTS
.
GUT
vol.
61
,
A171
-
A171
.
Houston Y, Lindsay JO, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R et al.
(
2012
)
.
Perspectives of transition care in inflammatory bowel disease: A survey
.
Gastrointestinal Nursing
vol.
10
,
(
1
)
30
-
35
.
Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ
(
2012
)
.
Retinoic acid production in the human intestine: antigen presenting cell retinaldehyde dehydrogenase activity is enhanced in inflammatory bowel disease
.
IMMUNOLOGY
.
vol.
137
,
78
-
78
.
Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, Pessoa-Lopes P, Mathew CG et al.
(
2012
)
.
Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota
.
INFLAMMATORY BOWEL DISEASES
vol.
18
,
(
6
)
1092
-
1100
.
Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ
(
2012
)
.
THE ROLE OF RDH10 AND RALDH ENZYMES IN RETINOIC ACID-MEDIATED IMMUNE REGULATION BY ANTIGEN PRESENTING CELLS IN THE HUMAN INTESTINE
.
GUT
.
vol.
61
,
A402
-
A403
.
Sebastian S, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R, Lindsay JO
(
2012
)
.
The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and paediatric gastroenterologists
.
JOURNAL OF CROHNS & COLITIS
vol.
6
,
(
8
)
830
-
844
.
Goodhand J, Hedin CR, Croft NM, Lindsay JO
(
2011
)
.
Adolescents with IBD: the importance of structured transition care
.
J Crohns Colitis
vol.
5
,
(
6
)
509
-
519
.
Benton B, Norton C, Lindsay J, Dolan S, Andreyev HJN
(
2011
)
.
Can Nurses Manage Gastrointestinal Symptoms Arising from Pelvic Radiation Disease?
.
CLIN ONCOL-UK
vol.
23
,
(
8
)
538
-
551
.
Ng SC, Benjamin JL, McCarthy NE, Hedin CRH, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al.
(
2011
)
.
Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease
.
Inflamm Bowel Dis
vol.
17
,
(
10
)
2027
-
2037
.
Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD et al.
(
2011
)
.
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease
.
Gut
vol.
60
,
(
7
)
923
-
929
.
Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ
(
2011
)
.
Expansion of Vδ2+T-Cells Occurs in Crohn's Disease Patients and Their Siblings: Impact of Therapy and Implications for Pathogenesis
.
Gastroenterology
vol.
140
,
(
5
)
s
-
489
.
Duncan J, Sastrillo M, Baker J, Younge L, Anderson S, Lindsay J, Sanderson J, Irving P
(
2011
)
.
AN AUDIT OF ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
.
GUT
.
vol.
60
,
Lindsay JO, Bloom S, Hamlin PJ, Hayward C, Percival F, Bean K, Bodger K
(
2011
)
.
AN EVALUATION OF THE IMPACT OF BIOLOGIC THERAPY ON SECONDARY CARE RESOURCE USE ASSOCIATED WITH THE MANAGEMENT OF CROHN'S DISEASE IN THE UK
.
GUT
.
vol.
60
,
Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ
(
2011
)
.
V Delta 2+T CELL EXPANSION IN CROHN'S DISEASE: IMPACT OF INFLAMMATION, DISEASE ACTIVITY AND TREATMENT
.
GUT
.
vol.
60
,
Sebastian S, Jenkins H, Arnott I, Croft N, Ahmad T, McCartney S, Russell RK, Lindsay JO
(
2011
)
.
Barriers to transition care in inflammatory bowel disease: a survey of adult and paediatric gastroenterologists in the UK
.
Gut
.
vol.
60
,
Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ
(
2011
)
.
Expansion of Vδ2+T-Cells Occurs in Crohn's Disease Patients and Their Siblings: Impact of Therapy and Implications for Pathogenesis
.
GASTROENTEROLOGY
.
vol.
140
,
S489
-
S489
.
Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR
(
2011
)
.
Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment
.
Aliment Pharmacol Ther
vol.
33
,
(
1
)
115
-
126
.
Ng SC, Benjamin JL, McCarthy NE, Hedin CR, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al.
(
2010
)
.
Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease
.
Inflamm Bowel Dis
.
McCarthy NE, Hedin CRH, Bhattacharjee S, James GS, Whelan K, Lindsay JO, Stagg AJ
(
2010
)
.
Circulating 'gut-tropic' V delta 2 T-cells are expanded in some Crohn's disease patients and their siblings but are ablated by azathioprine therapy
.
IMMUNOLOGY
.
vol.
131
,
107
-
107
.
Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A
(
2010
)
.
Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP(3)(+) T cell generation
.
IMMUNOLOGY
.
vol.
131
,
30
-
31
.
Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A
(
2010
)
.
Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP3(+) T cell generation
.
IMMUNOLOGY
.
vol.
131
,
134
-
135
.
Hedin CRH, Mullard M, Sharratt E, Jansen C, Sanderson JD, Shirlaw P, Howe LC, Djemal S et al.
(
2010
)
.
Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study
.
Inflamm Bowel Dis
vol.
16
,
(
12
)
2099
-
2108
.
Gellatly NL, Sanders TJ, Ahmed M, Mughal S, McCarthy NE, Pattni G, Lindsay JO, Stagg AJ
(
2010
)
.
Retinoic acid and aryl hydrocarbon receptor signalling: opposing effects on human dendritic cell differentiation and ability to imprint gut homing
.
IMMUNOLOGY
.
vol.
131
,
155
-
155
.
Vossenkämper A, Marchès O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong LA et al.
(
2010
)
.
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE
.
J Immunol
vol.
185
,
(
7
)
4118
-
4127
.
Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO
(
2010
)
.
Inflammatory bowel disease in young people: the case for transitional clinics
.
Inflamm Bowel Dis
vol.
16
,
(
6
)
947
-
952
.
Russo EA, O'Donnell S, Dearden J, Campbell S, Lindsay JO, O'Morain C, Orchard TR
(
2010
)
.
A RETROSPECTIVE SURVEY ON THE LONG-TERM EFFICACY OF THE SECOND BIOLOGIC IN THE MANAGEMENT OF CROHN'S DISEASE: RESULTS FROM A COMBINED ENGLISH IRISH COHORT
.
GUT
.
vol.
59
,
A64
-
A64
.
Benjamin JL, Koutsoumpas A, Hedin CRH, Ng SC, Prescott NJ, Pessoa-Lopes P, Mathew CG, Kamm MA et al.
(
2010
)
.
DEMOGRAPHIC, CLINICAL AND GENETIC FACTORS ASSOCIATED WITH DYSBIOSIS IN PATIENTS WITH ACTIVE CROHN'S DISEASE
.
GUT
.
vol.
59
,
A5
-
A5
.
Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, Hart AL, Kamm MA, Sanderson JD, Knight SC et al.
(
2010
)
.
NO CLINICAL BENEFIT OF PREBIOTICS IN THE TREATMENT OF ACTIVE CROHN'S DISEASE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL
.
GUT
.
vol.
59
,
A1
-
A2
.
Punekar YS, Sunderland T, Hawkins N, Lindsay J
(
2010
)
.
Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease
.
VALUE HEALTH
vol.
13
,
(
2
)
188
-
195
.
Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N et al.
(
2010
)
.
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland
.
EUR J GASTROEN HEPAT
vol.
22
,
(
3
)
334
-
339
.
Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A et al.
(
2010
)
.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
.
J CROHNS COLITIS
vol.
4
,
(
1
)
28
-
62
.
Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B et al.
(
2010
)
.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
.
J CROHNS COLITIS
vol.
4
,
(
1
)
63
-
101
.
Sharma N, Lindsay J
(
2009
)
.
Anti-TNF-Alpha-Induced Psoriasis - An Unusual Paradox
.
Case Rep Gastroenterol
vol.
3
,
(
3
)
404
-
407
.
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL
(
2009
)
.
Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine mercaptopurine
.
ALIMENT PHARM THER
vol.
30
,
(
6
)
614
-
620
.
Hedin CRH, Graczer M, Sanderson JD, Lindsay JO, Whelan K
(
2009
)
.
Probiotic and prebiotic use by patients with inflammatory bowel disease
.
Proceedings of The Nutrition Society
vol.
68
,
(
OCE1
)
Goodhand J, Tang JW, Naik S, Croft N, Lindsay JO
(
2009
)
.
W1115 Infliximab Use in Adolescents with Inflammatory Bowel Disease
.
Gastroenterology
vol.
136
,
(
5
)
a
-
657
.
Russo EA, Lindsay J, Campbell S, Hart AL, Hamlin PJ, Orchard TR, Arebi N, Nightingale J et al.
(
2009
)
.
EXPERIENCE ON THE USE OF ADALIMUMAB AS MAINTENANCE THERAPY IN CROHN'S DISEASE IN ENGLAND AND IRELAND
.
GUT
.
vol.
58
,
A61
-
A62
.
Goodhand J, Tang J, Naik S, Croft NM, Lindsay JO
(
2009
)
.
INFLIXIMAB USE IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE
.
GUT
.
vol.
58
,
A63
-
A64
.
Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH et al.
(
2009
)
.
Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England
.
Aliment Pharmacol Ther
vol.
29
,
(
3
)
308
-
314
.
Goodhand J, Swanson G, Hefferon M, Dawson R, Croft NM, Lindsay J
(
2009
)
.
P004 - Specialist transitional clinics for adolescents with IBD limit exposure to diagnostic radiation
.
Journal of Crohn's and Colitis
vol.
3
,
(
1
)
s12
-
s12
.
Goodhand J, Tang J, Naik S, Croft NM, Lindsay J
(
2009
)
.
P207 - Infliximab use in adolescents with IBD
.
Journal of Crohn's and Colitis
vol.
3
,
(
1
)
s92
-
s92
.
Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C et al.
(
2008
)
.
Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease
.
ALIMENT PHARM THER
vol.
28
,
(
8
)
973
-
983
.
Lindsay J, Punekar YS, Morris J, Chung-Faye G
(
2008
)
.
Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults
.
Aliment Pharmacol Ther
vol.
28
,
(
1
)
76
-
87
.
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney S, Bloom SL
(
2008
)
.
Efficacy of methotrexate in Crohns disease patients previously on thiopurine therapy
.
GASTROENTEROLOGY
vol.
134
,
(
4
)
A661
-
A661
.
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney S, Bloom SL, Lindsay JO
(
2008
)
.
Efficacy of methotrexate in ulcerative colitis
.
GASTROENTEROLOGY
vol.
134
,
(
4
)
A662
-
A662
.
Russo E, Harris A, Campbell S, Lindsay JO, Hart AL, Arebi N, Milestone A, Tsai HH et al.
(
2008
)
.
Experience of maintenance infliximab therapy for refractory ulcerative colitis in England
.
GASTROENTEROLOGY
vol.
134
,
(
4
)
A657
-
A657
.
Dawson R, Hefferon M, Croft N, Lindsay JO
(
2008
)
.
IBD in adolescents: A case control study of disease extent and therapeutic strategy
.
GASTROENTEROLOGY
vol.
134
,
(
4
)
A506
-
A506
.
Lindsay JO, Punekar Y, Morris J, Chung-Faye G
(
2008
)
.
Is scheduled maintenance treatment with infliximab cost effective in patients with Crohn's disease?
.
GASTROINTESTINAL ENDOSCOPY
.
vol.
67
,
AB318
-
AB318
.
Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al.
(
2008
)
.
Production of IL-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active Crohn's disease
.
GASTROENTEROLOGY
.
vol.
134
,
A653
-
A654
.
Dawson R, Hefferon M, Croft N, Lindsay JO
(
2008
)
.
T1201 IBD in Adolescents: A Case Control Study of Disease Extent and Therapeutic Strategy
.
Gastroenterology
vol.
134
,
(
4
)
a
-
506
.
Koutsoumpas A, Hedin CR, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al.
(
2008
)
.
The concentration and proportion of key bacterial groups of the faecal microbiota are different between smokers and non-smokers with active Crohn's disease
.
GASTROENTEROLOGY
vol.
134
,
(
4
)
A497
-
A497
.
Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al.
(
2008
)
.
W1201 Production of IL-10 By Colonic Dendritic Cells Is Associated with Higher Concentrations of Faecal Microbiota in Patients with Active Crohn's Disease
.
Gastroenterology
vol.
134
,
(
4
)
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney S, Bloom SL
(
2008
)
.
W1235 Efficacy of Methotrexate in Crohns Disease Patients Previously On Thiopurine Therapy
.
Gastroenterology
vol.
134
,
(
4
)
a
-
661
.
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney S, Bloom SL, Lindsay JO
(
2008
)
.
W1239 Efficacy of Methotrexate in Ulcerative Colitis
.
Gastroenterology
vol.
134
,
(
4
)
a
-
662
.
Ng SC, Koutsoumpas A, Hedin CRH, McCarthy N, Plamondon S, Kamm MA, Knight SC, Forbes A et al.
(
2008
)
.
P302 PRODUCTION OF IL-10 BY COLONIC DENDRITIC CELLS IS ASSOCIATED WITH HIGHER CONCENTRATIONS OF FAECAL MICROBIOTA IN PATIENTS WITH ACTIVE CROHN'S DISEASE
.
Journal of Crohn's and Colitis
vol.
2
,
(
1
)
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney SA, Bloom SL
(
2008
)
.
Efficacy of methotrexate in crohn's disease patients previously on thiopurine therapy
.
GUT
.
vol.
57
,
A152
-
A152
.
Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Bloom SL, Lindsay JO
(
2008
)
.
Efficacy of methotrexate in ulcerative colitis
.
GUT
.
vol.
57
,
A152
-
A152
.
Hedin CRH, Koutsoumpas A, Forbes A, Sanderson J, Stagg AJ, Knight SC, Whelan K, Lindsay JO
(
2008
)
.
Factors that limit recruitment to clinical trials in crohn's disease
.
GUT
.
vol.
57
,
A118
-
A118
.
Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al.
(
2008
)
.
Production of il-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active crohn's disease
.
GUT
.
vol.
57
,
A144
-
A144
.
Koutsoumpas A, Hedin CRH, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al.
(
2008
)
.
Smokers with active crohn's disease have differences in the concentration and proportion of key bacterial groups of the faecal microbiota
.
GUT
.
vol.
57
,
A152
-
A153
.
Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR
(
2007
)
.
Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals
.
AIDS
vol.
21
,
(
16
)
2177
-
2182
.
Hedin C, Whelan K, Lindsay JO
(
2007
)
.
Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials
.
Proc Nutr Soc
.
vol.
66
,
307
-
315
.
Wood E, Lindsay JO
(
2007
)
.
Trainee colonoscopy audit: North East Thames
.
GUT
.
vol.
56
,
A104
-
A104
.
D’Souza R, Lindsay J
(
2007
)
.
Biologic treatments in IBD
.
Clinical Dilemmas in Inflammatory Bowel Disease
,
Maywood ES, Lindsay JO, Karp J, Powers JB, Williams LM, Titchener L, Ebling FJP, Herbert J et al.
(
2006
)
.
Occlusion of the Melatonin‐Free Interval Blocks the Short Day Gonadal Response of the Male Syrian Hamster to Programmed Melatonin Infusions of Necessary Duration and Amplitude
.
Journal of Neuroendocrinology
vol.
3
,
(
3
)
331
-
337
.
Maywood ES, Grosse J, Lindsay JO, Karp JD, Powers JB, Ebling FJP, Herbert J, Hastings MH
(
2006
)
.
The Effect of Signal Frequency on the Gonadal Response of Male Syrian Hamsters to Programmed Melatonin Infusions
.
Journal of Neuroendocrinology
vol.
4
,
(
1
)
37
-
44
.
Hirri HM, Green PJ, Lindsay J
(
2006
)
.
Von Willebrand's disease and angiodysplasia treated with thalidomide
.
Haemophilia
vol.
12
,
(
3
)
285
-
286
.
Parkes G, Fairclough P, Lindsay JO
(
2006
)
.
Endoscopy in high risk cardiovascular patients
.
GUT
.
vol.
55
,
A56
-
A56
.
Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC et al.
(
2006
)
.
Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease
.
Gut
vol.
55
,
(
3
)
348
-
355
.
Lindsay J
(
2006
)
.
Medical management of diverticular disease: the role of bulking agents
.
Diverticular Disease: Emerging Evidence in a Common Condition
.
Editors:
Kruis, W, Forbes, A, Jauch, KW, Kreis, ME et al.
,
vol.
148
,
155
-
160
.
Al-Hassi HO, Lindsay JO, Whelan K, Gobin P, Forbes A, Kamm MA, Knight SC, Stagg AJ
(
2005
)
.
Modulation of intestinal dendritic cells (DC) in Crohn's disease patients taking a fructo-oligosaccharide prebiotic
.
IMMUNOLOGY
vol.
116
,
4
-
4
.
Mawdsley JED, Lindsay J, Rampton D
(
2005
)
.
Synbiotic therapy for ulcerative colitis
.
GUT
vol.
54
,
(
9
)
1346
-
1346
.
Lindsay JO, Whelan K, Stagg A, Gobin P, Omar H, Kamm MA, Knight SC, Forbes A
(
2005
)
.
Prebiotic fructo-oligosaccharide as a therapy for Crohn's disease: An open label trial
.
GUT
.
vol.
54
,
A23
-
A24
.
Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJF
(
2004
)
.
IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis
.
Dig Dis Sci
vol.
49
,
(
7-8
)
1327
-
1334
.
Lindsay JO
(
2004
)
.
Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis (Retraction of vol 52, pg 981, 2003)
.
GUT
vol.
53
,
(
5
)
774
-
774
.
Lindsay JO, Andreyev HJN, Vlavianos P, Westaby D
(
2004
)
.
Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass
.
Aliment Pharmacol Ther
vol.
19
,
(
8
)
901
-
905
.
Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Raoof S, Fong F, Fairbanks L et al.
(
2004
)
.
Pharmacogenetic profiling in azathioprine treatment: TPMT, ITPA, and MTHFR polymorphisms and toxicity
.
GUT
.
vol.
53
,
A105
-
A105
.
Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Soon SL, Fairbanks S, Duley J et al.
(
2004
)
.
Prospective study of thioguanine nucleotide measurement during azathioprine treatment for inflammatory bowel disease
.
GUT
.
vol.
53
,
A105
-
A105
.
Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ
(
2003
)
.
Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis
.
Gut
vol.
52
,
(
7
)
981
-
987
.
Lindsay JO, Vlavianos P, Andreyev HJN, Westaby D
(
2003
)
.
Enteral stents for the palliation of malignant gastric and duodenal obstruction
.
GUT
.
vol.
52
,
A72
-
A72
.
Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ
(
2003
)
.
Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis
.
Gut
vol.
52
,
(
3
)
363
-
369
.
Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te Velde A, Sol Rodriguez Pena M
(
2002
)
.
IL-10 gene therapy prevents TNBS-induced colitis
.
Gene Ther
vol.
9
,
(
24
)
1715
-
1721
.
Lindsay JO, van Montfrans C, te Velde AA, Brennan FM, Hodgson HJF, Pena MSR
(
2002
)
.
IL-10 gene therapy ameliorates TNBS induced colitis
.
GUT
vol.
50
,
A14
-
A14
.
Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF
(
2002
)
.
Local IL-10 gene therapy induces colonic IL-10 release and is therapeutic for murine colitis
.
GUT
vol.
50
,
A30
-
A30
.
Lindsay JO
(
2002
)
.
Interleukin-10 gene therapy: A cure for Crohn's disease?
.
CME Journal Gastroenterology, Hepatology and Nutrition
vol.
5
,
(
1
)
11
-
14
.
Lindsay JO, Hodgson HJ
(
2001
)
.
Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease?
.
Aliment Pharmacol Ther
vol.
15
,
(
11
)
1709
-
1716
.
Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM
(
2001
)
.
The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10
.
J Immunol
vol.
166
,
(
12
)
7625
-
7633
.
LINDSAY JO, Brennan FM, Hodgson HJF, Scheinin T, Ciesielski CJ
(
2001
)
.
The prevention and treatment of murine colitis using adenoviral vectors encoding interleukin-10
.
Journal of Immunology
vol.
166
,
7625
-
7633
.
Lindsay JO, Ciesielski CJ, Brennan FM, Hodgson HJ
(
2001
)
.
Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response
.
GASTROENTEROLOGY
vol.
120
,
(
5
)
A687
-
A688
.
Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ
(
2001
)
.
The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10
.
GASTROENTEROLOGY
vol.
120
,
(
5
)
A686
-
A686
.
Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF
(
2001
)
.
The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10
.
GUT
vol.
48
,
A109
-
A109
.
Lindsay JO, Taylor Robinson SD, Jackson JE, Walters JRF
(
2000
)
.
Erratum: The investigation of iron deficiency anemia - A hospital based audit (Hepato-Gastroenterology (1999) 46 (2887-2890))
.
Hepato-Gastroenterology
vol.
47
,
(
31
)
Lindsay JO, Robinson SD, Jackson JE, Walters JR
(
1999
)
.
The investigation of iron deficiency anemia--a hospital based audit
.
Hepatogastroenterology
vol.
46
,
(
29
)
2887
-
2890
.
Mumford AD, Vulliamy T, Lindsay J, Watson A
(
1998
)
.
Hereditary hyperferritinemia-cataract syndrome: two novel mutations in the L-ferritin iron-responsive element
.
Blood
vol.
91
,
(
1
)
367
-
368
.
Arnold JD, Mumford AD, Lindsay JO, Hegde U, Hagan M, Hawkins JR
(
1997
)
.
Hyperferritinaemia in the absence of iron overload
.
Gut
vol.
41
,
(
3
)
Kozaki K, Egawa H, Garcia-Kennedy R, Cox KL, Lindsay J, Esquivel CO
(
1995
)
.
Hepatic failure due to massive iron ingestion successfully treated with liver transplantation
.
Clinical Transplantation
vol.
9
,
(
2
)
85
-
87
.